Bristol-Myers Squibb Company (BMY)

61.26 -0.84 (-1.35%) At close: 4:00PM EST

Bristol-Myers Squibb Company

430 East 29th Street
14th Floor
New York, NY 10016
United States
212 546 4000
http://www.bms.com

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full Time Employees: 30,250

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Giovanni Caforio	Chairman & CEO	6.22M	N/A	1965
Mr. David V. Elkins	Exec. VP & CFO	3.62M	N/A	1968
Ms. Sandra Leung Esq.	Exec. VP & Gen. Counsel	2.92M	5.84M	1961
Dr. Christopher S. Boerner	Exec. VP & Chief Commercialization Officer	2.49M	N/A	1971
Mr. Rupert Vessey M.A.	Exec. VP and Pres of Research & Early Devel.	3.31M	N/A	1965
Mr. Paul von Autenried	Exec. VP & Chief Information Officer	N/A	N/A	1962
Mr. Timothy Power	VP & Head of Investor Relations	N/A	N/A	N/A
Mr. Adam Dubow	Sr. VP, Chief Compliance & Ethics Officer	N/A	N/A	1967
Ms. Ann M. Powell Judge	Exec. VP & Chief HR Officer	N/A	N/A	1966
Mr. Louis S. Schmukler	Exec. VP and Pres of Global Product Devel. & Supply	N/A	N/A	1956

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; and Nektar Therapeutics. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Corporate Governance

Bristol-Myers Squibb Company’s ISS Governance QualityScore as of December 2, 2020 is 5. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 5; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.